IFI44L Antibody

Role in Immune Regulation

IFI44L antibodies have been pivotal in elucidating IFI44L’s dual role as a feedback regulator of innate immunity and a positive modulator in antimicrobial responses:

• Antiviral Feedback Regulation: IFI44L binds FKBP5, reducing phosphorylation of IRF-3 and IκBα, thereby dampening excessive interferon (IFN) signaling . Antibodies confirmed reduced IFI44L protein levels in silenced cells, correlating with impaired viral replication .

• Antituberculosis Activity: In human macrophages, IFI44L knockdown increased Mycobacterium tuberculosis survival, highlighting its role in bacterial clearance. Antibodies validated IFI44L upregulation post-rifampicin treatment .

Cancer and Autoimmune Disease Linkages

• Lung Cancer: High IFI44L expression correlates with inhibited tumor growth and migration. Antibodies detected IFI44L downregulation in lung adenocarcinoma (LUAD), aiding prognostic modeling .

• Systemic Lupus Erythematosus (SLE): Promoter methylation of IFI44L serves as a diagnostic biomarker. While antibodies are not directly used in methylation studies, they enable protein-level validation in SLE research .

Biomarker Potential

• SLE Diagnosis: IFI44L promoter hypomethylation is a highly specific marker for childhood-onset SLE (cSLE), with an AUC of 0.867 . While antibodies are not directly used in methylation assays, they could complement epigenetic studies by quantifying protein levels.

• Cancer Prognosis: Low IFI44L expression in lung cancer correlates with poor survival. Antibodies enable validation of methylation-driven silencing in tumor tissues .

Therapeutic Targeting

• Viral Infections: IFI44L suppression reduces viral replication (e.g., influenza, LCMV). Antibodies may aid in monitoring therapeutic interventions targeting IFI44L .

• Tuberculosis: IFI44L enhances antimicrobial responses; antibodies could assess its expression during treatment .